Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials

References

• Korta DZ, Christiano AM, Bergfeld W, et al. Alopecia areata is a medical disease. J Am Acad Dermatol. 2018;78(4):832–834.
   PubMed Web of Science ®Google Scholar
• Strazzulla LC, Wang EHC, Avila L, et al. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol. 2018;78(1):1–12.
   PubMed Web of Science ®Google Scholar
• Lee HH, Gwillim E, Patel KR, et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: a systematic review and meta-analysis. J Am Acad Dermatol. 2020;82(3):675–682.
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA, Craiglow BG. Health-related quality of life (HRQoL) among patients with alopecia areata (AA): a systematic review. J Am Acad Dermatol. 2016;75(4):806–812.e3.
   PubMed Web of Science ®Google Scholar
• Liu LY, King BA, Craiglow BG. Alopecia areata is associated with impaired health-related quality of life: a survey of affected adults and children and their families. J Am Acad Dermatol. 2018;79(3):556–558.e1.
   PubMed Web of Science ®Google Scholar
• Rencz F, Gulácsi L, Péntek M, et al. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol. 2016;175(3):561–571.
   PubMed Web of Science ®Google Scholar
• Islam N, Leung PS, Huntley AC, et al. The autoimmune basis of alopecia areata: a comprehensive review. Autoimmun Rev. 2015;14(2):81–89.
   PubMed Web of Science ®Google Scholar
• Darwin E, Hirt PA, Fertig R, et al. Alopecia Areata: review of epidemiology, clinical features, pathogenesis, and new treatment options. Int J Trichology. 2018;10(2):51–60.
   PubMedGoogle Scholar
• Pratt CH, King LE, Jr., Messenger AG, et al. Alopecia areata. Nat Rev Dis Primers. 2017;3:17011.
   PubMed Web of Science ®Google Scholar
• Simakou T, Butcher JP, Reid S, et al. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun. 2019;98:74–85.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, King BA. Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis. J Invest Dermatol. 2014;134(12):2988–2990.
   PubMed Web of Science ®Google Scholar
• Craiglow BG, Liu LY, King BA. Tofacitinib for the treatment of alopecia areata and variants in adolescents. J Am Acad Dermatol. 2017;76(1):29–32.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Dai Z, Xing L, et al. Reversal of alopecia Areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–355.
   PubMed Web of Science ®Google Scholar
• Jabbari A, Sansaricq F, Cerise J, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia Areata, Totalis, and Universalis. J Invest Dermatol. 2018;138(7):1539–1545.
   PubMed Web of Science ®Google Scholar
• Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight. 2016;1(15):e89776.
   PubMed Web of Science ®Google Scholar
• Mackay-Wiggan J, Jabbari A, Nguyen N, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15):e89790.
   PubMed Web of Science ®Google Scholar
• Olamiju B, Friedmann A, King B. Treatment of severe alopecia areata with baricitinib. JAAD Case Rep. 2019;5(10):892–894.
   PubMedGoogle Scholar
• Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014;20(9):1043–1049.
   PubMed Web of Science ®Google Scholar
• King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study. J Am Acad Dermatol. 2021;85(4):847–853.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264–269, w64.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. Hoboken: John Wiley & Sons; 2019.
   Google Scholar
• King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med. 2022;386(18):1687–1699.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Nagata M, et al. Baricitinib improved alopecia areata concomitant with atopic dermatitis: a case report. J Dermatol. 2021;48(9):e472–e3.
   PubMed Web of Science ®Google Scholar
• Baricitinib  . LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
   Google Scholar
• Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58(Suppl 1):i34–i42.
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243.
   PubMed Web of Science ®Google Scholar
• Yu DA, Kim YE, Kwon O, et al. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: a systematic review and Meta-analysis. Indian J Dermatol Venereol Leprol. 2021;87(5):621–627.
   PubMed Web of Science ®Google Scholar
• King B, Mesinkovska N, Mirmirani P, et al. Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus kinase inhibitor, in moderate-to-severe alopecia areata. J Am Acad Dermatol. 2022;87(2):306–313.
   PubMed Web of Science ®Google Scholar
• King B, Guttman-Yassky E, Peeva E, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379–387.
   PubMed Web of Science ®Google Scholar
• Mikhaylov D, Glickman JW, Del Duca E, et al. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata. Arch Dermatol Res. 2022. DOI:10.1007/s00403-022-02336-0.
   PubMed Web of Science ®Google Scholar